

UMR Medical Policy Update Bulletin: May 2024

Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click here.

Medical Policy Updates

Policy Title	Status	Effective Date
Beds and Mattresses	Revised	Jun. 1, 2024
Breast Reduction Surgery	Updated	Jun. 1, 2024
Cardiac Event Monitoring	Revised	Jun. 1, 2024
Category III Codes	Updated	May 1, 2024
Electrical Bioimpendance for Cardiac Output Measurement	Retired	May 1, 2024
Enteral Nutrition (Oral and Tube Feeding) (for Commercial only)	Updated	May 1, 2024
Gastrointestinal Motility Disorders, Diagnosis and Treatment	Revised	Jul. 1, 2024
Laser Interstitial Thermal Therapy	Retired	May 1, 2024
Mobility Devices, Options, and Accessories	Updated	May 1, 2024
Orthognathic (Jaw) Surgery	Revised	Jun. 1, 2024
Preimplantation Genetic Testing and Related Services	Revised	Jun. 1, 2024
Speech Generating Devices	Updated	May 1, 2024
Walkers	Revised	Jun. 1, 2024

Medical Benefit Drug Policy Updates

Policy Title	Status	Effective Date
Aduhelm® (Aducanumab-Avwa)	Updated	May 1, 2024
Adzynma (ADAMTS13, Recombinant-Krhn)	Updated	May 1, 2024
Entyvio® (Vedolizumab)	Revised	Jun. 1, 2024
Ilumya® (Tildrakizumab-Asmn)	Revised	Jun. 1, 2024
Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®)	Revised	Jun. 1, 2024
Ketalar® (Ketamine) and Spravato® (Esketamine)	Revised	Jun. 1, 2024
Maximum Dosage and Frequency	Revised	Jun. 1, 2024
Provider Administered Drugs – Site of Care	Updated	May 1, 2024
Qalsody® (Tofersen)	Revised	Jun. 1, 2024
Rituximab (Riabni [®] , Rituxan [®] , Ruxience [®] , & Truxima [®])	Revised	Jun. 1, 2024
Uplizna® (Inebilizumab-Cdon)	Revised	Jun. 1, 2024
Veopoz [™] (Pozelimab-Bbfg)	Revised	Jun. 1, 2024
Viltepso® (Viltolarsen)	Revised	Jun. 1, 2024
Vyepti® (Eptinezumab-Jjmr)	Revised	Jun. 1, 2024

UMR Medical Policy Update Bulletin: May 2024

Policy Title	Status	Effective Date
Vyjuvek® (Beramagene Geperpavec-Svdt)	Revised	Jun. 1, 2024
Xolair® (Omalizumab)	Revised	Jun. 1, 2024

General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

UMR is a wholly owned subsidiary of UnitedHealthcare, a part of UnitedHealth Group. UMR is a third-party administrator (TPA) for self-funded plans.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UMR Medical Policies and Medical Benefit Drug Policies is available at **UHCprovider.com** > Policies and Protocols for Healthcare Providers > For Commercial Plans > UnitedHealthcare | UMR Medical & Drug Policies.